SEC Form 4 · accession 0001209191-17-041270
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martha J Demski
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 21, 2017 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.19 | Jun 20, 2017 | A | 12,450 | A | — | Jun 20, 2027 | Common Stock | 12,450 | 12,450 | D |
Explanation of responses
- F1Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan.